Tuning, Rather than Blocking, Immunity in IBD

The Bio Report by Levine Media Group

Apr 15, 202635:47Business

The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection risks, and drive high treatment cycling. Abivax is betting that fine-tuning, rath...

Related Episodes

Continue listening to more episodes from The Bio Report.

How a Breast-Milk-Derived Peptide Could Change Bladder Cancer Care

Sep 23, 2026 - 26:00

For people with non-muscle-invasive bladder cancer, treatment can involve repeated procedures, a high ris...

Targeting Visceral Fat with RNA Therapeutics

Sep 16, 2026 - 29:11

GLP-1 therapies have dramatically reshaped obesity care, but the next generation of medicines may be judg...

Engineering T-Cell Engagers for Solid Cancers

Sep 9, 2026 - 31:59

T-cell engagers have delivered important advances in blood cancers, but extending their success to solid...

Resetting Severe Allergies at Their Cellular Source

Sep 2, 2026 - 33:17

For people with severe allergies and mast cell diseases, the risk of a dangerous reaction can shape every...

Innovating ADCs with Dual Targeting and Smarter Delivery

Aug 26, 2026 - 29:35

Antibody-drug conjugates have established themselves as an important cancer-treatment modality, but their...

Targeting the Brain’s Immune System in Alzheimer’s Disease

Aug 19, 2026 - 34:19

Alzheimer’s disease remains one of medicine’s most intractable challenges. While existing therapies may a...

How Gilead Is Building Durable Oncology and Immunology Franchises

Aug 12, 2026 - 38:31

Gilead today stands at an inflection point. Its HIV and broader virology business still account for rough...

Protecting the Brain After Stroke

Aug 5, 2026 - 29:16

Ischemic stroke remains one of the most devastating and resource‑intensive emergencies in medicine, with...